Pharma: Page 30
-
Mario Tama via Getty Images
J&J to acquire ADC drug developer Ambrx for $2B
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
By Ned Pagliarulo • Jan. 8, 2024 -
Getty Images
Novo taps Flagship startups to develop drugs for obesity, MASH
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
By Kristin Jensen • Jan. 4, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Getty Images
Roche joins startup Remix in bet on another way to drug RNA
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
By Ben Fidler • Jan. 3, 2024 -
Permission granted by Novartis
Novartis deepens ties with Voyager via $100M gene therapy deal
The deal builds on an existing alliance and includes tools Novartis will use in gene therapies for Huntington’s disease and spinal muscular atrophy.
By Delilah Alvarado • Jan. 2, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers to acquire brain drug developer Karuna for $14B
The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.
By Ned Pagliarulo , Ben Fidler • Updated Dec. 22, 2023 -
Courtesy of Sanofi
Sanofi scraps a top ADC prospect after study setback
The drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline.
By Ben Fidler • Dec. 21, 2023 -
Warren Little via Getty Images
GSK adds to ADC dealmaking with second Chinese biotech pact
The deal with Hansoh Pharma, GSK’s second this year, gives the company an antibody-drug conjugate in testing for solid tumors like lung cancer.
By Jonathan Gardner • Dec. 20, 2023 -
Courtesy of Merck & Co.
Merck gets FDA decision date for new pneumococcal vaccine
The company’s shot targets 21 strains of pneumococcal bacteria and, if approved, would compete with Pfizer’s Prevnar 20.
By Delilah Alvarado • Dec. 19, 2023 -
Courtesy of Novo Nordisk
Foundation behind Novo Nordisk to invest $260M in vaccine R&D
The newly established initiative, which consists of a research center and an accelerator, will focus on developing vaccines for tuberculosis, influenza and group A streptococcus.
By Delilah Alvarado • Dec. 18, 2023 -
Courtesy of Novartis
Amgen finds a new top scientist in Novartis veteran Bradner
Jay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen’s chief scientific officer and head of R&D.
By Jacob Bell • Dec. 15, 2023 -
Anna Moneymaker via Getty Images
Supreme Court to rule on abortion pill access
The court's decision on mifepristone, expected by June, could have far-reaching implications for the FDA as well as the biotechnology industry.
By Delilah Alvarado • Dec. 13, 2023 -
Drew Angerer via Getty Images
Pfizer to deepen cost cuts as latest sales forecasts miss expectations
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
By Jonathan Gardner • Dec. 13, 2023 -
Christopher Furlong via Getty Images
AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.
By Delilah Alvarado • Dec. 12, 2023 -
Permission granted by Bristol-Myers Squibb
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
The lucrative alliance, potentially worth more than $8 billion, continues a run of dealmaking for a class of cancer drugs that’s surged in popularity in recent years.
By Ben Fidler • Dec. 12, 2023 -
Permission granted by Celonis
Sponsored by CelonisLife sciences leaders invest in process mining to accelerate digital transformation
Research from Everest Group shows how life sciences leaders are investing in process mining to speed time-to-market, improve regulatory compliance and drive innovation.
By Rachel Stolba • Dec. 11, 2023 -
Jeenah Moon via Getty Images
Pfizer marks progress for successor sickle cell drug at ASH
While new gene therapies for the blood disease grabbed headlines at ASH, Pfizer presented fresh data for an oral drug meant to build on its marketed therapy Oxbryta.
By Gwendolyn Wu • Dec. 10, 2023 -
Courtesy of Merck KGaA
German Merck’s MS drug falls short in pair of Phase 3 tests
The results dim the outlook of BTK inhibitors as potential autoimmune disease treatments and could have ramifications for Roche, Sanofi and Novartis.
By Kristin Jensen • Dec. 6, 2023 -
Permission granted by Novartis
Novartis gets FDA approval of closely watched rare disease drug
The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.
By Ned Pagliarulo • Dec. 6, 2023 -
Getty Images
Pfizer, after delay, completes enrollment in Lyme vaccine trial
The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.
By Delilah Alvarado • Dec. 5, 2023 -
Mario Tama via Getty Images
J&J pitches investors on sales growth from cancer, immune disease drugs
The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.
By Ned Pagliarulo • Dec. 5, 2023 -
Courtesy of Roche
Roche joins obesity drug chase with $2.7B deal for startup Carmot
The acquisition of Carmot, which had been planning an IPO, will hand Roche three weight loss medicines in early clinical testing.
By Ben Fidler • Dec. 4, 2023 -
Getty Images
Pfizer plans for oral obesity drug hit new setback
The company won’t continue development of a twice-daily dose of its experimental weight loss medicine danuglipron after study data showed high rates of side effects.
By Ned Pagliarulo • Dec. 1, 2023 -
Getty Images
Gilead to lay off staff at cell therapy unit Kite
The cuts will impact 7% of the cancer drug division’s employees, although about 90 new roles will be created around “areas of growth.”
By Delilah Alvarado • Nov. 29, 2023 -
Novartis sees brighter sales future as R&D revamp continues
The pharma has overhauled its pipeline this year, cutting R&D programs outside of its four main therapeutic areas.
By Ned Pagliarulo • Nov. 28, 2023 -
Chip Somodevilla via Getty Images
Deep DivePharma benefited from basing business overseas. An international tax effort could spur a rethink.
U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
By Jonathan Gardner • Nov. 28, 2023
Previous
